Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 152.97M shares rose 39.2% year over year, behind the +71.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +50.6% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +39.2% toward the trailing-twelve-month pace of +71.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 152.97M USD
- Year-over-year change
- +80.3%
- 4-year CAGR
- +38.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 152.97M | +80.3% |
| FY2024 | 2024-12-31 | 84.82M | +15.0% |
| FY2023 | 2023-12-31 | 73.79M | +64.6% |
| FY2022 | 2022-12-31 | 44.82M | +8.6% |
| FY2021 | 2021-12-31 | 41.29M | — |
Weighted Avg Shares (Diluted) vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 weighted avg shares (diluted) of 158.02M shares is the 2nd highest of the 11 companies compared; the peer median is 63.58M shares.
- Its year-over-year change of +71.7% is the highest of 11, against a peer median of +3.2%.
- Over three fiscal years its annual growth of +50.6% compares with a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 167.44M | +37.0% | +15.3% | |
| LTM Mar 2026 | 158.02M | +71.7% | +50.6% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
| LTM Mar 2026 | 94.18M | +3.6% | +15.4% | |
| LTM Mar 2026 | 74.4M | -1.9% | +17.6% | |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
| LTM Mar 2026 | 60.91M | +28.1% | +103.4% | |
| LTM Mar 2026 | 58.91M | +1.6% | +15.2% | |
| LTM Mar 2026 | 40.92M | +29.8% | +18.6% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| Peer median (excluding TNYA) | 63.58M | +3.2% | +15.4% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.